This protocol covers the management of follicular lymphoma that has undergone confirmed histological transformation to diffuse large B-cell lymphoma (DLBCL) in patients who have previously received anthracycline-based chemotherapy and remain clinically fit for consolidation with high-dose therapy and autologous stem cell rescue (HDT-ASCR).
Transformed follicular lymphoma (tFL) with confirmed histological transformation to DLBCL. Prior exposure to anthracycline chemotherapy, with or without rituximab. Patient assessed as fit for high-dose consolidation with autologous stem cell rescue.
In this setting, treatment generally involves second-line salvage chemotherapy regimens used for DLBCL, selected in the context of prior anthracycline exposure and the patient's eligibility for HDT-ASCR. The complete regimen selection, sequencing, and eligibility criteria are detailed in the full protocol.
The treatment of patients with tFL previously exposed to anthracyclines with or without rituximab is varied and, in general, involves second-line regimens used for DLBCL in patients who are eligible for consolidation with HDT-ASCR.
Offer second-line salvage chemotherapy regimens used for DLBCL in tFL who have received prior anthracycline and are fit for HDT-ASCR.
View source ↗